BROADCASTS.com

Host: Julie E. Chang, MD
\n\n\n \n

Bruton\u2019s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. Still, many patients discontinue treatment because of adverse events and treatment resistance. As science moves forward in understanding why some patients do not respond well to treatment with BTKi, a new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible therapeutic alternative.

Now\u2019s the time to learn about this promising new treatment path for CLL and MCL. In this activity, featuring four concise modules, an expert discusses the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.